Previous Close | 39.15 |
Open | 38.21 |
Bid | 38.98 x 48300 |
Ask | 38.99 x 51100 |
Day's Range | 38.21 - 39.56 |
52 Week Range | 33.75 - 44.81 |
Volume | |
Avg. Volume | 671,447 |
Market Cap | 8.745B |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | 27.52 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 1.18 (2.94%) |
Ex-Dividend Date | Jan 30, 2024 |
1y Target Est | N/A |
Q1 2024: Net sales of $459 million (-5% actual rates, -5% constant exchange rates, CER); diluted EPS of $0.36 and adjusted diluted EPS of $0.46 // Net sales at CER of $462 million ahead of outlook for at least $455 million CER and adj. diluted EPS of $0.47 CER ahead of $0.44 CER outlook // Excluding COVID-19 product groups, net sales decline 1% CER // Diagnostics sales +5% CER on double-digit CER growth in QuantiFERON and QIAstat‑Dx // 25.7% adjusted operating income margin on efficiency gains v
Launch of QIAseq xHYB Mycobacterium tuberculosis Panel for research use, enabling culture-free whole genome sequencing from complex samples // Panel significantly accelerates TB outbreak tracking and supports detection and management of antimicrobial resistance, critical needs in TB surveillance and control // Building upon success of leading diagnostics test QuantiFERON-TB Gold Plus as QIAGEN extends portfolio for TB management and control amid globally rising incidence ratesVenlo, the Netherla
Venlo, The Netherlands, April 09, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the first quarter 2024. Press release date / time: Monday, April 29, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Tuesday, April 30, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time. Three options for joining the conference call Register for call back connection - C